Researchers have reported promising results for a drug called tovorafenib in treating pediatric low-grade gliomas caused by BRAF mutations. This once-weekly medication showed a response rate of 67%, with tumor reduction or halted growth in many cases. Its convenience and lower impact on quality of life make it a significant step forward for inoperable brain tumors in children. The drug is awaiting FDA approval, with plans for further trials to explore its combination with immunotherapies.